Three Cases of Recurrent Thyroid Cancer Involving the Perforation of Adjacent Structures Caused by Lenvatinib after External Radiation Therapy

Shimo, Toshiro; Yoshidome, Katsuhide; Anno, Kana; Tori, Masayuki

doi:10.3919/jjsa.79.283

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some clinical reports have highlighted the positive treatment effects with the concurrent use of TKI and EBRT for thyroid cancer without severe toxicities [20,21]. However, other reports have shown that TKI could induce severe toxicities in patients with extended tumor invasion to the carotid artery or a history of neck irradiation [7,22]. No prospective trials have investigated the combined therapy with irradiation and lenvatinib for thyroid cancer; therefore, there is a need for careful consideration and patient discussion before clinically applying this combined therapy.…”

Section: Discussionmentioning

confidence: 99%

Treatment Outcomes of External Beam Radiation Therapy for Unresectable Locally Advanced Thyroid Cancer with or without Metastasis: A Retrospective Single-Center Study

et al. 2021

View full text Add to dashboard Cite

We evaluated treatment outcomes of external beam radiation therapy (EBRT) for unresectable locally advanced thyroid cancer (LATC) with or without metastasis. We enrolled 11 LATC patients who underwent EBRT (median age: 76 (45–83) years; six males and five females). Eastern Cooperative Oncology Group performance statuses of 0 (n = 3), 1 (n = 1), 2 (n = 6), and 3 (n = 1) were observed. Histologic types included papillary carcinoma (n = 5), anaplastic carcinoma (n = 3), and squamous cell carcinoma (n = 3). The organs invaded by the tumor that caused it to be deemed unresectable were common carotid artery (n = 5), trachea (n = 4), aorta (n = 1) and larynx (n = 1). The median follow-up time was 6 months. One, seven, two, and one patient showed complete response (CR), partial response (PR), stable disease, and progressive disease, respectively. The rate of local CR+PR was 73%; moreover, 75% of patients achieved a >30% tumor size reduction within 6 months. The median local progression-free survival of patients with local CR+PR was 11.5 (4–68) months. The median overall survival was 6 (1–68) months. Grade 3 acute complications occurred in five (45%) patients. No patients had Grade 4 or 5 complications. In conclusion, EBRT reduced the tumor volume in 75% of LATC patients without inducing severe toxicity. This therapy should be considered as a treatment option for LATC.

show abstract

Section: Discussionmentioning

confidence: 99%